Propanc Pty Ltd

Novartis Ag

The University of Sydney

Ralf Brandt

David Tosh

Julian Norman Kenyon

Fernando Felquer

Paul Rodney Clayton

Carl-Henrik Heldin

Peter Traxler

Terence O'Reilly

Markus Wartmann

John David Rothermel

Elisabeth Buchdunger

Kristian Pietras

Arne Östman

Julian Kenyon

The present invention relates to compositions, methods, uses and kits for treating cancer. In particular, the invention relates to compositions and methods of treating cancer in a subject comprising administering chymotrypsinogen in certain amounts, for example greater than about 0.1 mg/kg, and trypsinogen in an amount, for example, greater than about 0.02 mg/kg, thereby treating cancer. The invention also relate to compositions and methods for treating cancer in a subject comprising chymotrypsinogen and trypsinogen wherein the weight ratio of chymotrypsinogen:trypsinogen is greater than 8:1.

Proenzyme composition

The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumor cells.

Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.

Combination comprising a signal transduction inhibitor and an epothilone derivative

Growing community of inventors

Greenwith, Australia

Ralf Brandt